Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

Tsukuda, Mamoru; Kida, Akinori; Fujisawa, Masato; Kono, Nobuji; Yoshihara, T.; Hasegawa, Yasuhisa; Sugita, Minoru

doi:10.1038/sj.bjc.6602804

Cited by 89 publications

(73 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S-1 has recently been adopted as a front line chemotherapeutic regimen for the treatment of gastric cancer in Japan, based on the findings of several randomized trials. [9][10][11] Furthermore, S-1 has been also identified as an effective agent for the treatment of colorectal, 12 head and neck, 13 breast, 14 non-small-cell lung, 15 biliary tract 16 and pancreatic cancers. 17 5-FU is not used in patients with prostate cancer because of its poor efficacy and severe side effects.…”

Section: Introductionmentioning

confidence: 99%

Low‐dose docetaxel enhances the sensitivity of S‐1 in a xenograft model of human castration resistant prostate cancer

Hasegawa¹,

Miyajima²,

Kosaka³

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

S-1 is a recently developed dihydropyrimidine dehydrogenase inhibitor fluoropyrimidine and has demonstrated high maximum plasma 5-Fluorouracil (5-FU) levels with mild toxicity, and an oral formulation has resulted in an improvement in patient quality of life. The aims of the present study were to determine the efficacy of S-1 or S-1 combined with docetaxel (DOC) using castration resistant prostate cancer (CRPC) cells and to explore their clinical potential for treating CRPC patients. LNCaP cells, androgen dependent prostate cancer (ADPC) cells and C4-2 cells, which are a CRPC subline of LNCaP cells, were used. Specimens obtained from ADPC and CRPC patients were also evaluated. The CRPC specimens and C4-2 cells exhibited significantly lower thymidylate synthase (TS) expression, a target of 5-FU, than the ADPC specimens and LNCaP cells. In vitro, C4-2 cells exhibited higher sensitivity to 5-FU than LNCaP cells. In C4-2 xenograft model, S-1 monotherapy suppressed tumor growth and low-dose DOC enhanced the anti-tumor effect of S-1. In vitro, low-dose DOC, which did not induce G2/M arrest, increased p53 and p21 and resulted in down-regulation of TS in C4-2 cells, and down-regulation of TS is considered to be responsible for the synergistic effect of S-1 in vivo. The present findings indicate that CRPC patients with androgen ablation may be good candidates for 5-FU based chemotherapy, and these regimens have attractive therapeutic potential for clinical practice, and they may have a significant impact on therapeutic options.

show abstract

Section: Introductionmentioning

confidence: 99%

Low‐dose docetaxel enhances the sensitivity of S‐1 in a xenograft model of human castration resistant prostate cancer

Hasegawa¹,

Miyajima²,

Kosaka³

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Administration of treatment. resection for gastric cancer, squamous cell carcinoma of head and neck, breast cancer and NSCLC (19,(22)(23)(24)33,34). The 5-year DFS and OS were almost the same between the S-1 group and the paclitaxel plus carboplatin group.…”

Section: Discussionmentioning

confidence: 59%

S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stageï¿½II/IIIA non‑small‑cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Abstract.The majority of patients with completely resected stage II or IIIA non-small-cell lung cancer (NSCLC) require adjuvant chemotherapy to improve survival following surgery. In the present trial, the 2-year disease-free survival (DFS), and the feasibility and safety of S-1 as an adjuvant chemotherapy for advanced lung cancer were evaluated. A total of 40 patients with completely resected stage II or IIIA NSCLC were enrolled and randomized to receive postoperative chemotherapy with either up to 4 cycles of paclitaxel plus carboplatin (arm A) or with up to 1 year of S-1 (arm B). The primary endpoint was 2-year DFS. The secondary endpoints were feasibility and toxicity. A total of 40 patients were enrolled, but 3 were excluded in accordance with the exclusion criteria. The remaining 37 patients were analyzed. The 2-year DFS rate was 54.2% in arm A and 84.2% in arm B. Overall, 15/18 (83.3%) patients completed 4 cycles of paclitaxel plus carboplatin and 13/19 (68.4%) completed 1-year of S-1adjuvant chemotherapy. Of the 18 (16.7%) patients in arm A, 3 experienced grade 3 or 4 adverse events, while none in arm B experienced such events. Therefore, S-1 chemotherapy for patients with completely resected stage II or IIIA NSCLC was a feasible and safe regimen, and it may therefore be considered as a potential adjuvant chemotherapy option for advanced NSCLC.

show abstract

“…[18][19][20][21][22][23] Recently, Tsukuda et al reported that 2 weeks of S-1 followed by a 1-week rest period was more feasible for adjuvant chemotherapy of locoregionally advanced squamous cell carcinoma of the head and neck region than 4 weeks of S-1 followed by a 2-week rest period. 24,25 Therefore, we selected 2 weeks of S-1 followed by a 1-week rest period as the regimen for our patients.…”

Section: Discussionmentioning

confidence: 99%

Two elderly patients with advanced maxillary gingival carcinoma with complete response to concurrent radiotherapy and S-1 chemotherapy

Yoshizawa

Nozaki

Yoshida

et al. 2010

Asian Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Abbreviations: OSCC, oral squamous cell carcinoma; CR, complete response; BSA, body 2 surface area; RECIST, response evaluation criteria in solid tumors; CTCAE v3.0, common terminology criteria for Adverse Events version 3.0; ADL, activities of daily living.3 Abstract: The use of the novel oral fluoropyrimidine anticancer drug S-1 as a single-agent or in combined chemotherapy has been reported to be useful for the treatment of advanced oral cancer.We report two elderly patients with advanced oral cancer who achieved complete response (CR) after concurrent radiotherapy and S-1 chemotherapy. Patient 1 was an 81-year-old woman who had a 50 × 40 mm tumor erosion in the right upper gingival region. At 2.5 years after the end of concurrent radiotherapy and S-1 chemotherapy, tumor relapse was observed, although CR continued temporarily. The patient died 3 years after the end of concurrent radiotherapy and S-1 chemotherapy due to tumor relapse and high blood pressure resulting in deterioration of patient condition. Patient 2 was an 89-year-old woman who had a 40 × 30 mm tumor ulcer in the right gingiva. Neither relapse nor metastasis was seen, and patient condition remained good for the 3 years after concurrent radiotherapy and S-1 chemotherapy. In both patients, MRI showed that the tumor had deeply invaded the palatal bone, almost reaching the nasal cavity, with metastasis 4 to the right upper superior internal jugular nodes. In both patients, biopsy showed a well-differentiated squamous cell carcinoma. Concurrent radiotherapy and S-1 chemotherapy induced CR without severe adverse effects.

show abstract

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

Cited by 89 publications

References 25 publications

Low‐dose docetaxel enhances the sensitivity of S‐1 in a xenograft model of human castration resistant prostate cancer

Low‐dose docetaxel enhances the sensitivity of S‐1 in a xenograft model of human castration resistant prostate cancer

S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stageï¿½II/IIIA non‑small‑cell lung cancer

Two elderly patients with advanced maxillary gingival carcinoma with complete response to concurrent radiotherapy and S-1 chemotherapy

Contact Info

Product

Resources

About